Home > Healthcare > Medical Devices > Therapeutic Devices > us dialysis market
Get a free sample of U.S. Dialysis Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of U.S. Dialysis Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The market is characterized by a competitive landscape with numerous national and regional players vying for market share. Major key players are offering advanced products and standardized services contributing to the market expansion. Regional providers are also expanding their services to capture local market segments. Competition drives innovation, improving patient care and operational efficiency. Strategic partnerships, acquisitions, and technological advancements further enhance the competitive dynamics in the market.
Some of the eminent market participants operating in the U.S. dialysis industry include:
South Atlantic U.S. dialysis industry size is anticipated to grow at 5.1% CAGR between 2024 and 2032 led by rapidly aging population in Florida, Georgia, and North and South Carolina
Asahi Kasei Corporation, B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, DaVita Inc., Fresenius Medical Care AG & Co., Innovative Renal Care., Medtronic plc, Nikkiso Co., Ltd., Nipro Corporation, Toray Industries Inc., and U.S. Renal Care, Inc.
The hemodialysis type segment in the market recorded USD 25.4 billion in 2023 as it is the standard treatment for the majority of patients with ESRD, particularly those who may not be candidates for home-based therapies.
U.S. dialysis industry was valued at USD 28.8 billion in 2023 and is expected to exhibit 5.5% CAGR from 2024 to 2032 attributed to the rising number of end-stage renal diseases (ESRD) patients and increasing incidence of diabetes